openPR Logo
Press release

Alzheimer’s Association Long Island Announces Release of Latest Report on Alzheimer’s Disease

11-17-2011 06:41 AM CET | Associations & Organizations

Press release from: Alzheimer's Association Long Island

/ PR Agency: PRMG
Alzheimer’s Association Long Island announced the release of the most recent report about Alzheimer’s disease. “Alzheimer’s from the Frontlines: Challenges a National Alzheimer’s Plan Must Address” provides a look into the unrelenting challenges brought on by this disease by offering insights and perspectives from individuals across the country who participated in the Alzheimer’s Association’s public input process. The Association and over 70 of its chapters hosted 132 input sessions throughout the country to discuss the obstacles this disease forces on millions of American families each year. The release of the report coincides with the month of November being National Alzheimer’s Awareness Month.

Over the course of this national public input process, several key challenges emerged repeatedly in discussions. These obstacles included increasing awareness of the impact of Alzheimer’s, fostering an environment that offers more effective treatments faster, providing better care throughout the disease process and ensuring better support today for caregivers.

During the month of August, Alzheimer’s Association Long Island hosted three public input sessions to solicit views, comments and perspectives from stakeholders in the Alzheimer’s community to assist in the development of a successful National Alzheimer’s Plan.

Currently the sixth-leading cause of death, there is currently no means to prevent, cure or even slow down the progression of Alzheimer’s disease. There are an estimated 5.4 million Americans living with Alzheimer’s and, according to this report, nearly 16 million Americans will have the disease by 2050. Of that number, 414,000 reside in New York State and 60,000 are from Long Island.

In response to this rapidly growing problem, Alzheimer’s Association Long Island has further demonstrated its commitment to raise funding for Alzheimer’s research and provide support for those affected by this disease. The organization hosted its 2011 Walk to End Alzheimer’s on September 10 and its inaugural East End Walk to End Alzheimer’s on October 1.

“As Americans continue to live longer, this devastating disease will affect more people each year,” says Mary Ann Malack-Ragona, Executive Director/CEO, Alzheimer’s Association Long Island. “Our goal is to raise funds for crucial research and provide additional resources to ease the emotional and financial toll on those caring for a loved one with Alzheimer’s.”

The full text of the Alzheimer’s Association’s “Alzheimer’s from the Frontlines: Challenges a National Alzheimer’s Plan Must Address” report can be viewed at www.alz.org/napa. For more information about Alzheimer’s Association Long Island, please contact Mary Ann Malack-Ragona, Executive Director/CEO at (631) 820-8068 or visit www.alz.org/longisland.

About Alzheimer’s Association

The Alzheimer's Association is the world’s leading voluntary health organization in Alzheimer’s care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer’s. For more information, visit www.alz.org.

Hank Russell, Public Relations Director
The Public Relations and Marketing Group
156 North Ocean Avenue
Patchogue, NY 11772
(631) 207-1057
hrussell@theprmg.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alzheimer’s Association Long Island Announces Release of Latest Report on Alzheimer’s Disease here

News-ID: 200864 • Views:

More Releases for Alzheimer

Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
Anti-β-Alzheimer Therapies Market : Consumption, Revenue, Applications With Maj …
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal'
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Alzheimer Diagnostic Tests Market - Medical Devices Pipeline Assessment, 2017 | …
"The Latest Research Report Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Alzheimer Diagnostic Tests Market GlobalData's Medical Devices sector report, Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Alzheimer Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as